Abstract
Dr. Ronald Desrosiers of the New England Primate Research Center at the Harvard Medical School provides his opinions on the HIV-1deltakURNe vaccine strain. Dr. Desrosiers explains what this strain represents and how it was chosen for live-attenuated HIV vaccine human safety trials. Further, Desrosiers discusses the balance in using highly attenuated vaccines and protection effectiveness, whether it is possible for the vaccine strain to revert to a disease-causing form, the possibility of transmission of a vaccine virus to unvaccinated individuals, and the issue of cancer development through insertional mutagenesis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 45-46 |
| Number of pages | 2 |
| Journal | Journal of the International Association of Physicians in AIDS Care |
| Volume | 4 |
| Issue number | 3 |
| State | Published - Jan 1 1998 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Does the HIV-1deltakURNe vaccine strain hold the key to curbing HIV infection? An interview with Ronald Desrosiers, PhD. / Desrosiers, Ronald Charles.
In: Journal of the International Association of Physicians in AIDS Care, Vol. 4, No. 3, 01.01.1998, p. 45-46.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Does the HIV-1deltakURNe vaccine strain hold the key to curbing HIV infection? An interview with Ronald Desrosiers, PhD.
AU - Desrosiers, Ronald Charles
PY - 1998/1/1
Y1 - 1998/1/1
N2 - Dr. Ronald Desrosiers of the New England Primate Research Center at the Harvard Medical School provides his opinions on the HIV-1deltakURNe vaccine strain. Dr. Desrosiers explains what this strain represents and how it was chosen for live-attenuated HIV vaccine human safety trials. Further, Desrosiers discusses the balance in using highly attenuated vaccines and protection effectiveness, whether it is possible for the vaccine strain to revert to a disease-causing form, the possibility of transmission of a vaccine virus to unvaccinated individuals, and the issue of cancer development through insertional mutagenesis.
AB - Dr. Ronald Desrosiers of the New England Primate Research Center at the Harvard Medical School provides his opinions on the HIV-1deltakURNe vaccine strain. Dr. Desrosiers explains what this strain represents and how it was chosen for live-attenuated HIV vaccine human safety trials. Further, Desrosiers discusses the balance in using highly attenuated vaccines and protection effectiveness, whether it is possible for the vaccine strain to revert to a disease-causing form, the possibility of transmission of a vaccine virus to unvaccinated individuals, and the issue of cancer development through insertional mutagenesis.
UR - http://www.scopus.com/inward/record.url?scp=0032015693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032015693&partnerID=8YFLogxK
M3 - Article
C2 - 11365180
AN - SCOPUS:0032015693
VL - 4
SP - 45
EP - 46
JO - Journal of the International Association of Physicians in AIDS Care
JF - Journal of the International Association of Physicians in AIDS Care
SN - 1081-454X
IS - 3
ER -